UNSPSC 51184016: Tolbutamide

This classification denotes an anti-diabetic agent with the molecular formula C12H18N2O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 982XCM1FOI, chemically known as urea, 1-butyl-3-(p-tolylsulfonyl)- but more generally known as tolbutamide, which bears US NIH Compound Identifier 5505. European Medicines Agency schedules Tolbutamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11150MIG.

UNSPSC 51184016 Tolbutamide is a Commodity code covering the supply of this specific antidiabetic pharmaceutical product to state and local government facilities. State and local agencies purchase tolbutamide through cooperative purchasing vehicles and multi-source pharmaceutical procurement agreements that consolidate demand across multiple jurisdictions and allow them to negotiate volume-based pricing with manufacturers and authorized drug wholesalers. The purchasing bodies include state health departments, Medicaid programs, state correctional facilities, state employee health plans, and participating municipalities and counties that join cooperative alliances to leverage collective buying power for both brand-name and generic medications.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products, with tolbutamide as one product within the broader solicitation scope. MMCAP's approach requires manufacturers to supply through three authorized wholesalers — AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC — and participate in the cooperative's pricing structure, which weights price competitiveness at 75 percent of evaluation and applies a 3 percent administrative fee on all purchases. Awarded manufacturers must maintain relationships with at least two of the three wholesalers, comply with current Good Manufacturing Practices and Drug Supply Chain Security Act requirements, and carry insurance coverage including $5 million commercial general liability and $2 million network security and privacy liability. The resulting agreements are effective July 1, 2026, with a two-year term for new vendors and optional MMCAP extensions thereafter, covering participating state and local government facilities across multiple states including Minnesota and Oregon.